published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61] COPE – Coalition V, 2022 1.56 [0.39; 6.24] COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28] PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71] 1.35[0.43; 4.19]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COPE – Coalition V, 2022, COVID-PEP Severity (Skipper), 2020, PATCH Cohort 1 (Amaravadi), 202140%2,181moderatenot evaluable clinical deteriorationdetailed resultsPATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68] 0.51[0.07; 3.68]PATCH Cohort 1 (Amaravadi), 202110%28NAnot evaluable clinical improvementdetailed resultsCOVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.36[0.87; 2.11]COVID-PEP Severity (Skipper), 202010%395NAnot evaluable clinical improvement (14-day)detailed resultsCOVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11] 1.36[0.87; 2.11]COVID-PEP Severity (Skipper), 202010%395NAnot evaluable hospitalizationdetailed resultsBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76] COPE – Coalition V, 2022 0.77 [0.52; 1.13] PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93] 0.77[0.55; 1.10]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COPE – Coalition V, 2022, PATCH Cohort 1 (Amaravadi), 202130%1,694moderatenot evaluable mechanical ventilationdetailed resultsCOPE – Coalition V, 2022 1.32 [0.46; 3.79] 1.32[0.46; 3.79]COPE – Coalition V, 202210%1,369NAnot evaluable ICU admissiondetailed resultsCOPE – Coalition V, 2022 0.84 [0.43; 1.63] 0.84[0.43; 1.63]COPE – Coalition V, 202210%1,369NAnot evaluable adverse eventsdetailed resultsOut of scaleBCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85] COVID-PEP Severity (Skipper), 2020 2.75 [1.80; 4.21] 21.73[0.36; 1295.07]BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COVID-PEP Severity (Skipper), 2020299%776moderatenot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-05-01 00:43 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290